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Epidemiological data consistently rank hepatocellular carcinoma (HCC) as one of the
leading causes of cancer-related deaths worldwide, often posing severe economic
burden on health care. While the molecular etiopathogenesis associated with genetic
and epigenetic modifications has been extensively explored, the biological influence of
the emerging field of epitranscriptomics and its associated aberrant RNA modifications
on tumorigenesis is a largely unexplored territory with immense potential for discovering
new therapeutic approaches. In particular, the underlying cellular mechanisms of
different hallmarks of hepatocarcinogenesis that are governed by the complex dynamics
of m6A RNA methylation demand further investigation. In this review, we reveal the
up-to-date knowledge on the mechanistic and functional link between m6A RNA
methylation and pathogenesis of HCC.
Keywords: hepatocellular carcinoma, epitranscriptomics, m6A RNA methylation, cancer hallmarks, writers,
erasers, readers
INTRODUCTION
The advent of advancements in next-generation sequencing technologies along with the launch of
highly specific antibodies capable of identifying chemically modified nucleotides broke new ground
for RNA methylation, recently coined “epitranscriptomics,” to gain prominence as a dynamic and
reversible modification, analogous to epigenetic regulations. While previous studies have largely
focused on the genetic and epigenetic factors that contribute to hepatocellular carcinoma (HCC),
research into deciphering the role of epitranscriptomics in triggering liver-related malignancies is
still in its infancy. Thus, the dynamics of m6A RNA methylation on the molecular pathogenesis of
HCC is an emerging field that requires extensive research, with immense potential to unlock new
therapeutic targets to combat hepatocarcinogenesis.
HEPATOCELLULAR CARCINOMA
Hepatocellular carcinoma accounts for over 80% of hepatic neoplasms worldwide, imposing heavy
disease burden by being the fourth most common cause of cancer-associated mortality worldwide
(El-Serag and Rudolph, 2007; Fitzmaurice et al., 2019). The HCC incidence has been estimated to
be more prevalent in males than females and widespread in certain regions including middle and
western Africa, eastern and southern Asia, Polynesia, and Melanesia (Ferlay et al., 2010). Several risk
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factors contribute to HCC, among which chronic alcohol
consumption, cirrhosis, viral hepatitis (due to infection with
hepatitis virus B and C), non-alcoholic fatty liver disease
(NAFLD), and ingestion and exposure to aflatoxin and
aristolochic acid majorly contribute toward the onset of
hepatocarcinogenesis (Yang and Roberts, 2010). Chronic
hepatitis B and C account for the most frequent etiologies
especially in particular geographical locations (such as
Oceania, western sub-Saharan Africa, and central Asia)
with inadequate medical resources and also the predisposition
to gradual hepatic damage and ensued cirrhosis and HCC
(Bosch et al., 2004; Stanaway et al., 2016). Pathologically,
the regenerating nodules synthesized during cirrhosis create
a favorable microenvironment for the transformation of
dysplastic hepatocytes to neoplastic lesions ultimately leading
to HCC (Alqahtani et al., 2019). In addition, the manifestation
of HCC is seldom reported in congenital hepatic fibrosis,
ataxia telangiectasia, familial cholestatic cirrhosis, familial
polyposis coli, fetal alcohol syndrome, and neurofibromatosis
(Leong and Leong, 2005).
Surveillance for HCC, principally in high-risk individuals,
includes ultrasonography and biomarker testing (Yang and
Roberts, 2010). While emerging research shows several promising
biomarkers, pertaining to HCC diagnosis, prognosis, and clinical
staging, such as vascular endothelial growth factor (VEGF;
Biselli-Chicote et al., 2012), epidermal growth factor (EGF;
Kedmi et al., 2015), platelet-derived growth factor (PDGF;
Campbell et al., 2005), insulin-like growth factor (IGF; Enguita-
Germán and Fortes, 2014), mammalian target of rapamycin
(mTOR), and microRNAs (Mínguez and Lachenmayer, 2011;
Okada et al., 2015), currently alpha-fetoprotein (AFP) is the
only clinically approved serological biomarker (Beudeker and
Boonstra, 2020). In fact, high expression levels of EGF and
VEGF that promote proliferation and angiogenesis, respectively,
have been associated with early recurrence of HCC, while
TGF and PDGF receptor protein overexpression has been
shown to activate profibrotic pathways that induce liver
tumorigenesis (Campbell et al., 2005; Biselli-Chicote et al.,
2012; Kedmi et al., 2015). Patients diagnosed with early-stage
HCC opt for curative treatment options including surgical
removal, orthotopic liver transplantation, or percutaneous
ablation, usually performed with radiofrequency ablation or
percutaneous alcohol injection. For patients with unremovable
tumors, transarterial chemoembolization, carried out by infusing
a concoction of chemotherapeutic agents, and transarterial
radioembolization, involving treatment with radioactive particles
are recommended. Besides, treatment options for patients with
advanced stages of cancer include multikinase inhibitors such as
sorafenib, lenvatinib, and regorafenib (Llovet et al., 2008; Yang
and Roberts, 2010).
The initiation and progression of HCC are facilitated by
various genetic and epigenetic alterations, which are built up
in hepatocytes, eventually leading to malignant transformation
as a result of the conversion of proto-oncogenes to oncogenes
and the loss of functional mutation or dosage changes
of tumor suppressor genes. Genetic abnormalities include
chromosomal translocation, single-nucleotide polymorphisms,
and targeted gene loss and deletion (Singh et al., 2018). Epigenetic
changes, on the other hand, inflict no permanent genetic
alterations; instead, they affect gene transcription and chromatin
integrity. Epigenetic modifications that drive HCC include gene-
specific DNA hypo- and hypermethylation, global genomic
hypomethylation, aberrant histone modifications, and altered
expression of microRNA (Leong and Leong, 2005; Libbrecht
et al., 2005). Furthermore, deregulation of signal transduction
pathways that govern cell cycle, proliferation, differentiation, and
apoptosis, including the Wnt/β-catenin pathway, Ras/Raf/MAPK
pathway, PI3/AKT/mTOR pathway, JAK/STAT pathway, and
ubiquitin–proteasome pathway (UPP), can lead to onset of liver
tumorigenesis (Alqahtani et al., 2019).
HALLMARKS OF HEPATOCELLULAR
CARCINOMA
Hanahan and Weinberg comprehensively presented the
exploration of distinct and complementary traits that trigger
tumorigenesis and metastatic propagation by logically organizing
them into major hallmarks to rationally appreciate the
complexities of neoplastic maladies (Hanahan and Weinberg,
2000, 2011). These hallmarks of cancer are as follows: sustaining
proliferative signaling, eluding growth suppressors, evading
immune destruction, facilitating replicative immortality,
aiding in tumor-promoting inflammation, triggering invasion
and metastasis, prompting angiogenesis, inducing genomic
instability, preventing cell apoptosis, and deregulating cellular
energetics (Hanahan and Weinberg, 2011). The hallmarks of
cancer with regard to HCC are reviewed below and summarized
in Figure 1.
Sustaining mitogenic signaling and evading growth
suppressors in tumor cells are feasibly the most fundamental
characteristics of tumor cells, unlike in normal cells that
regulate cell homeostasis, especially pertaining to releasing
growth-promoting signals (Hanahan and Weinberg, 2011;
Sever and Brugge, 2015). For instance, HCC occurs largely as
a result of uninhibited cellular proliferation resulting from a
series of dysregulations in normal cell cycle regulators such as
cyclin-dependent kinases (CDKs). Given the unique regenerative
aptitude of hepatocytes, any reprobate cell proliferation,
upregulation of CDKs, or alterations in CDK-related downstream
signaling pathways and CDK inhibitors could potentiate the
onset of hepatocarcinogenesis (Shen et al., 2019).
The role of the immune system in eradicating certain
neoplasia and micrometastases is an area that demands
further researching. Owing to the ever-alert surveillance nature
of immune cells in eliminating tumor cells, it is worth
exploring the potential mechanisms that solid tumors have
acquired in successfully evading immunological destruction.
In HCC, immune checkpoint inhibitors such as CTLA-
4 and PD-L1 regulate the immunosuppression of chronic
inflammation brought about by persistent expression of certain
cytokines and immune cell recruitment (Makarova-Rusher
et al., 2015; Xu et al., 2018). Contrary to previous beliefs
that immune responses largely represented an attempt to
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FIGURE 1 | Hallmarks of hepatocellular carcinoma. Several liver tumorigenesis-driving hallmarks affect the downstream cellular mechanisms by sustaining
proliferative signaling, eluding growth suppressors, evading immune destruction, facilitating replicative immortality, aiding in tumor-promoting inflammation, triggering
invasion and metastasis, prompting angiogenesis, inducing genome instability, preventing cell apoptosis, and deregulating cellular energetics. Figure modified from
Hanahan and Weinberg (2011).
eliminate tumorigenesis, an ever-growing assemblage of scientific
evidence suggests the paradoxical effect of tumor-induced
inflammation in aiding neoplasias (DeNardo et al., 2010;
Qian and Pollard, 2010). HCC-associated inflammation could
be chiefly attributed to recruitment of inflammatory cells in
the tumor microenvironment, extrinsic pathways that activate
pattern recognition receptors by pathogen-associated molecule
patterns, or damage-associated molecule patterns (DAMPs)
released from liver cells undergoing apoptosis (Yu et al., 2018).
Tumor cells ensure continued survival by withstanding
two crucial aspects that limit unlimited replicative potential
in normal cells: senescence and crisis/apoptosis. It has been
observed in cirrhotic liver cells that telomerase, an enzyme that
prevents telomere shortening and ensuing cellular senescence,
has an impaired activity coupled with subsequent shortening of
telomeres implicating senescence of hepatocytes (Nault et al.,
2019). To circumvent this and enable replicative perpetuity,
telomerase reactivation is elicited through aberrant mutations
in TERT promoter, leading to uncontrolled cell proliferation
and subsequent HCC development (Donaires et al., 2017;
Nault et al., 2019).
The multistep mechanism of invasion and metastasis is
broadly regulated by epithelial–mesenchymal transition (EMT),
heterotypic involvement of neoplastic stromal cells, and plasticity
in the invasive growth properties disseminated by cancer cells
(Hugo et al., 2007; Klymkowsky and Savagner, 2009; Egeblad
et al., 2010). It has been proposed that in HCC, signaling
through the Ras/MAPK pathway could liaise with the TGF-
β signal transduction pathway in driving the shift from EMT,
rendering tumor cells their mobility (Matsuzaki et al., 2000).
Another hallmark of cancer, inducing angiogenesis, involves
tumor-associated neovasculature that activates an “angiogenic
switch” through the regulation of countervailing inducers and
inhibitors, such as VEGF-A and thrombospondin-1, respectively,
Hanahan and Weinberg (2011). Given the high invasive nature
of HCC, it is not surprising to observe VEGF overexpression in
the precancerous stages of dysplastic and cirrhotic liver tissues
further to a strong correlation of VEGF expression and tumor
grading of HCC (Hamdy et al., 2020).
Acquisition of genomic instability could convene selective
advantage on neoplastic cells, enabling them to outgrow and
dominate in a tumor microenvironment niche. Premalignant
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cells drive tumorigenesis by enhancing their sensitivity to
mutagenic agents and compromising the “surveillance systems”
that monitor cellular genomic integrity (Jackson and Bartek,
2009). Notably in HCC, genetic alterations are instigated
by chromosome and microsatellite instability, accumulated
somatic mutations, single-nucleotide polymorphisms, and
deregulated signaling pathways (Niu et al., 2016; Rao et al.,
2017). Resisting cell death is another crucial hallmark of
tumorigenesis. While programmed cell apoptosis, resulting
from certain elevated oncogenic signaling mechanisms and
hyperproliferation-associated DNA damage, functions as a
natural barrier to carcinogenesis, certain tumors eventually
progress to high-grade malignancy and induce drug resistance,
through an “apoptotic switch” (Adams and Cory, 2007; Hanahan
and Weinberg, 2011). Especially in HCC, apoptosis-associated
mechanisms are governed by attenuation of p53 function
through telomere-induced chromosomal instability (Farazi et al.,
2006), downregulation of pro-apoptotic genes such as B cell
lymphoma 2 (Mott and Gores, 2007), growth factor-mediated
cell survival (Llovet and Bruix, 2008), and overactivation of
anti-apoptotic pathways associated with fas pathway inhibitors
(Lee et al., 2001).
Tumor energy metabolism, an emerging hallmark, confers the
metabolic preferences of cancer cells to favor aerobic glycolysis,
famously characterized as the Warburg effect (Vander Heiden
et al., 2009). Gluconeogenesis in HCC is driven by upregulating
facilitative glucose transporters, notably GLUT1 (Yamamoto
et al., 1990), significant elevation of hypoxic regulators such
as HIF-1α (Yang et al., 2014), and expression of rad and myc
oncogenes that fuels glycolysis (Tiniakos et al., 1989).
Tumor pathogenesis encompasses a complex network of
regulatory pathways involving various genetic, epigenetic, and
epitranscriptomic mechanisms. Aberrant epitranscriptomic RNA
modifications have also been shown to drive tumorigenesis
due to dysregulation of RNA processing, polyadenylation,
translation initiation, splicing, stability, and localization, which
affect translation of tumor suppressors and oncogenes (Ferlay
et al., 2010). Since each cancer type differs from the other, it
is not surprising that different tumor promoters may activate
different oncogenic pathways, directly or indirectly affecting
RNA modifications, such as m6A and thereby their protein
levels. It is evidenced that downregulation of RNA m6A
modification can promote tumor progression in several types of
cancers, such as glioblastoma, endometrial tumors, and leukemia
(Yang and Roberts, 2010). Therefore, it is crucial to explore
the relationship between aberrant RNA m6A modifications
and hepatocarcinogenesis to better understand the disease
etiopathogenesis.
m6A RNA MODIFICATION AND
ASSOCIATED REGULATORS
First identified in 1970, N6-methyladenosine (m6A) is the most
profuse and reversible internal modification omnipresent in
eukaryotic mRNA and has been the focus in the emerging field
of epitranscriptomics (Wu et al., 2016). While research has
previously explored the crucial role of epigenetic regulation,
pertaining to DNA and histone methylation, the dynamic
function of m6A RNA modification is a relatively novel
and largely unexplored territory, with regard to discovering
mechanisms of gene expression regulation (Strahl and Allis,
2000; Suzuki and Bird, 2008; Wu et al., 2016). With the advent
of new next-generation sequencing approaches such as MeRIP-
seq, over 12,000 highly conserved methylated peaks have been
identified in human and mouse transcriptomes, revealing the
correlation between m6A abundance and the structural and
functional aspects of a specific gene. m6A modification refers to
the addition of a methyl group to the nitrogenous base present at
the sixth position of the adenine residue in the RNA (Figure 2;
Desrosiers et al., 1974). With an approximate estimate of 0.1–
0.4% of adenosines subjected to alterations, an average of two to
three m6A-modified sites have been predicted to be present in
every mRNA transcript (Wei et al., 1975). Topological analysis
has indicated that methylation occurs mainly near the 3′-UTR
region, on adenosine residues presenting in a consensus motif of
RRm6ACH (R = G/A, H = A/C/U; Figure 2; Csepany et al., 1990;
Meyer Kate et al., 2012).
Owing to its dynamic and reversible nature, m6A RNA
methylation is modulated by a multi-subunit complex of
methyltransferase proteins known as “writers,” which add
methyl groups to the adenosine; demethylases known as
“erasers,” which aid in the removal of methyl groups; and
RNA binding proteins known as “readers,” which bind to
methylated RNA and regulate discrete downstream mechanisms
(Karthiya and Khandelia, 2020).
Writers
The methyltransferase complex is composed of several subunits
with key methylases such as METTL3 and METTL14 and
regulator proteins such as WTAP, METTL16, ZC3H13, and
RBM15/15B (Karthiya and Khandelia, 2020). METTL3 and
METTL14, which contain an S-adenosyl methionine (SAM)
binding motif, form a core heterodimer and co-localize in nuclear
speckles, with the former acting as an enzymatic component
and the latter as an allosteric activator (Śledź and Jinek, 2016;
Wang et al., 2016). The Wilms tumor 1 (WT1)-associated protein
(WTAP), a splicing factor that modulates methylation, regulates
the position of the heterodimer while indirectly increasing the
catalytic capacity of methyltransferases (Ping et al., 2014; Zhang
et al., 2019). RBM15/15B interacts with the methyltransferase
complex with the aid of WTAP, further liaises with chromatin
remodeling complexes, and modulates cortical development by
recruiting the writer complex. ZC3H13 zinc finger protein,
on the other hand, acts as a recruiter protein promoting
localization of the writer complex in the nucleus. A relatively
novel methyltransferase, METTL16, directs deposition of specific
RNAs as well as U6 small nuclear RNA in addition to maintaining
SAM homeostasis by adding methyl groups to the SAM synthase
transcript, thereby gaining control of its stability and splicing
mechanisms. Choosing a transcript for methylation is carried out
by recruiting methyltransferases to specific promoters by certain
transcription factors in addition to being influenced by histone
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FIGURE 2 | Overview of m6A RNA methylation and m6A mapping technologies. (A) N6-methyladenosine refers to the addition of a methyl group to the nitrogenous
base present at the sixth position of the adenine residue in the RNA. (B) Topological analysis has indicated that m6A methylation occurs mainly near the 3′-UTR
region, on adenosine residues presenting in a consensus motif of RRm6ACH (R = G/A, H = A/C/U). Transcriptome-wide sequencing technologies for mapping m6A
(C), MeRIP-seq (D), PA-m6A-seq (E), miCLIP (F), and m6A-LAIC-seq (G) SCARLET. Figure modified from Dominissini et al. (2012); Liu et al. (2013), and Li et al.
(2016).
modifications such as H3K36me3 and H4K20me1 (Kolasinska-
Zwierz et al., 2009; Tilgner et al., 2009; Zaccara et al., 2019).
Erasers
Eraser proteins function primarily by shaping the m6A
landscape dynamically. RNA demethylases such as fat mass
and obesity-associated protein (FTO; Jia et al., 2011) and
AlkB family member 5 (ALKBH5; Zheng et al., 2013) belong
to the ALKB family of dioxygenases that appear to have
a restricted role under normal physiological conditions,
with prominent functions in particular organs such as
the testes and in certain ailments. Functionally, FTO
performs an indirect role by sequentially oxidizing N6-
methyladenosine to N6-formyladenosine, with an intermediate
hydroxymethyladenosine, while ALKBH5 catalyzes direct
removal of methylation (Chen and Wong, 2020).
Readers
The fate of mRNAs containing m6A is predominantly
determined by different categories of m6A-binding proteins,
termed “readers,” such as YT521-B homology (YTH) domain
family, heterogeneous nuclear ribonucleoproteins (hnRNPs),
and IGF 2 mRNA-binding proteins (IGFBPs). Such proteins
govern the m6A-related downstream cellular mechanisms in
tumorigenesis, viral replication, adipogenesis, hemopoiesis, and
immune regulation (Zhao et al., 2020).
The YTH domain-containing family (YTHDF) comprises
YTHDF1, YTHDF2, YTHDF3, YTHDC1, and YTHDC2
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proteins that recognize m6A in a methylation-dependent
manner. As the first cytoplasmic reader protein to be discovered,
YTHDF2 performs the function of degrading methylated RNA
by directly recruiting CCR4–NOT deadenylation complex to the
target transcript, inherently reducing its stability and thereafter
directing bound mRNA to relevant decay sites such as processing
bodies (Wang et al., 2014; Du et al., 2016). YTHDF1 protein
significantly augments mRNA translation efficiency through
interactions with the translation initiation factor eIF3 and in
some cases in an m7G-cap-dependent manner (Wang et al.,
2015; Liu et al., 2020a). YTHDC1 plays a pertinent role in
exon selection during gene splicing (Roundtree and He, 2016).
YTHDC2 acts as a putative RNA helicase that governs RNA levels
during cell meiosis by forming a complex with meiosis-specific
coiled-coil domain-containing protein (MEIOC; Hsu et al., 2017;
Jain et al., 2018).
Heterogeneous nuclear ribonucleoprotein protein family
encompasses hnRNPs such as A2/B1 (HNRNPA2B1), C
(HNRNPC), and G (HNRNPG), which have affinity to
structural alterations induced by m6A methylation, commonly
known as “m6A switch” (Liu et al., 2015, 2017; Wu et al.,
2018). HNRNPA2B1 modulates alternative splicing of mRNA
transcripts and processes primary miRNAs through DGCR8-
directed interactions (Alarcón et al., 2015). HNRNPC and
HNRNPG impact pre-mRNA processing and pre-mRNA
alternative splicing, respectively, via interactions with
phosphorylated carboxy-terminal domain of enzyme RNA
polymerase (Zarnack et al., 2013; Liu et al., 2017). The IGFBP
family proteins use a KH RNA binding domain to identify
m6A-containing transcripts and exert their function by actively
recruiting RNA stabilizers such as HuR to protect mRNA
transcripts from degradation (Chen and Wong, 2020).
m6A Mapping Technologies
The field of epitranscriptomics began gaining prominence with
the development of methylated RNA immunoprecipitation/m6A
sequencing (MeRIP/m6A-seq), capable of conducting a site-
specific analysis of m6A modification-based transcriptomic
studies. This technique together with ChIP-seq depends
on a specific m6A antibody to pull down m6A-containing
transcripts that can subsequently be mapped by next-generation
sequencing technologies (Zhang and Hamada, 2020). However, to
circumvent issues with regard to identifying m6A-modified site,
improved technologies such as photo-crosslinking-associated
sequencing (PA-m6A-seq), which uses a photo-crosslinking
method, and even single-nucleotide resolution m6A mapping
are attainable (Linder et al., 2015). Furthermore, with
additional UV crosslinking stratagems through techniques
such as m6A individual-nucleotide-resolution crosslinking
and immunoprecipitation (miCLIP), specific mutations and
truncation profiles affected by the presence of m6A can be
mapped precisely (Zhang et al., 2019).
Another contemporary technique for high-resolution
m6A mapping is the site-specific cleavage and radioactive
labeling followed by ligation-assisted extraction and thin-layer
chromatography (SCARLET). As implicated by the name, the
method involves site-specific cleavage and radiolabeling followed
by splint ligation by DNA ligase, gel purification, and, finally,
an analysis using thin-layer chromatography (Liu et al., 2013;
Maity and Das, 2016). While this technique cannot employ high-
throughput sequencing, newer methods such as m6A level and
isoform characterization sequencing (m6A-LAIC-seq), which
are compatible with high-throughput sequencing, have lately
begun to see the limelight (Molinie et al., 2016). Also, since total
RNA is ample without the requirement of enriching the targeted
fraction of RNA, this method is deemed suitable for quantifying
methylation levels in low abundance RNAs such as tRNAs
(Linder et al., 2015). These m6A mapping technologies have been
summarized in Figure 2. More recently, the third-generation
single-nucleotide sequencing technologies such as Nanopore
Direct Sequencing, capable of mapping RNA modifications
at single base resolution, show promise in identifying m6A
sites with improved accuracy (El-Serag and Rudolph, 2007;
Fitzmaurice et al., 2019).
In recent years, several bioinformatics tools and databases
addressing different purposes have been developed to organize
and integrate complex datasets pertaining to m6A RNA
modifications and its associated regulators. An interactive
analysis of epitranscriptomic sequencing for m6A site
identification can be performed by databases such as deepEA
(Zhai et al., 2020) and iMRM (Liu and Chen, 2020), while
RNAWRE (Nie et al., 2020), and M6A2Target (Deng et al., 2020)
deposit m6A regulator datasets. Furthermore, comprehensive
information on reliable m6A methylation sites and peaks from
MeRIP-seq data are summarized in m6A-Atlas (Tang et al.,
2020) and REPIC (Liu et al., 2020b), respectively. Bioinformatics
resources such as RMDisease (Chen K. et al., 2020) and RMVar
(Luo et al., 2020) can aid in better understanding the association
between various epitranscriptomic modifications and their
probable disease relevance.
m6A RNA METHYLATION REGULATORS
AND HALLMARKS OF
HEPATOCELLULAR CARCINOMA
The impact of m6A writers, readers, and erasers on key pathways
that regulate the development of HCC are summarized in
Figure 3 and Table 1.
“Writers” in Hepatocellular Carcinoma
Hallmarks
In a recent study, Chen et al. (2018) identified suppressor
of cytokine signaling 2 (SOCS2) as a downstream target
of methyltransferase METTL3-induced m6A modification via
the m6A reader protein YTHDF2-dependent pathway (Chen
et al., 2018). Previous studies have investigated the function
of SOCS2 as a cytokine-inducible negative regulator in Janus
kinase/signal transduction and activation of the JAK/STAT
pathway (Yoshikawa et al., 2001). SOCS2 downregulation is
significantly correlated to advanced Tumor, Node, and Metastasis
staging in addition to being a prognostic marker in HCC
(Qiu et al., 2013). SOCS2 has also been associated with the
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FIGURE 3 | RNA methylation on transcripts induces a spectrum of intracellular mechanisms that are primarily driven by methylases, demethylases, and RNA binding
proteins. Such mechanisms regulate RNA translation, nuclear transport, degradation, exon inclusion 3′-end processing, and alternative splicing. Deregulation of
these complex network of mechanisms involving key signal transduction pathways that govern cell cycle, proliferation, differentiation, and apoptosis eventually
influence the progression of hepatocellular carcinoma. Refer to Table 1 for information on the regulatory patterns of m6A regulators with regard to HCC. Figure
modified from Karthiya and Khandelia (2020).
negative or positive regulation of GH, IGF-1, PRL, IL-2, IL-3,
EPO, LIF, EGF, leptin, and IFN-α-dependent signaling pathways,
which are involved in tumorigenesis (Rico-Bautista et al., 2006).
Another potential regulatory mechanism involves mitogen-
response SUMOylation of METTL3 that leads to upregulation of
EMT genes, which inherently show a strong positive correlation
to enhanced metastatic dissemination in HCC via m6A
methyltransferase regulation of Snail, transcription factor, in
mRNA homeostasis (Xu et al., 2020). Such mechanisms highlight
the importance of m6A-mediated methylation regulation,
especially on EMT, as the latter promotes drug resistance, tumor
recurrence, and metastasis, all of which contribute to HCC
(Wang and Zhou, 2013).
Another study explored the m6A modification of RDM1
(RAD52 motif 1) mRNA induced by the overexpression of
METTL3 in clinical HCC samples. The methyltransferase
represses the expression of RDM1, which in turn mechanistically
disrupts protein stability of tumor suppressors such as
p53 protein and subsequent suppression of Raf and ERK
phosphorylation, eventually promoting tumorigenesis in HCC
(Chen S. L. et al., 2019). Thus, such cascade of downstream
processes leading to cancer could be solely traced back to the
oncogenic behavior of METTL3.
Mechanistic studies revealed positive modulation of another
subunit of methyltransferase, METTL14, on pri-miR126, a
metastasis-inducing miRNA mechanism in a DGCR8-dependent
manner (Ma et al., 2017). As a critical constituent of the
canonical microprocessor complex for microRNA biogenesis,
DGCR8 maintains the upregulation or deregulation of certain
tumor-specific miRNAs that intrinsically contribute to enhanced
cell proliferation, evasion of apoptosis via angiogenesis, and
initiation of invasion and metastatic pathways, especially
in HCC (Chu et al., 2014; Deng et al., 2019). Emerging
evidence suggests that aberrantly downregulated miR126 boosted
the poor overall survival associated with HCC (Bao et al.,
2018). Restoring miR126 inhibited cell proliferation in HCC,
arrested cell cycle advancement, and induced cell apoptosis
(Zhao et al., 2015). Thus, the tumor-suppressive function
of METTL14 could be a potential target in developing
therapeutics targeting HCC.
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TABLE 1 | Role of m6A methylome in hepatocarcinogenesis.
m6A regulator type m6A regulator Expression pattern Function in hepatocellular carcinoma* References




Writer METTL3 Upregulated SUMOylation of METTL3 leads to upregulation of EMT
via m6A regulation of Snail transcription factor.
Xu et al., 2020
Writer METTL3 Upregulated METTL3 represses the expression of RDM1, which in
turn disrupts p53 protein stability.
Chen S. L.
et al., 2019
Writer METTL14 Downregulated METTL14 liaises with microprocessor protein DGCR8
and positively modifies the microRNA 126 activity in an
m6A-dependent manner.
Ma et al., 2017
Writer WTAP Upregulated WTAP drives methylation of ETS1 leading to epigenetic
silencing of ETS1 via a HuR-dependent manner.
Chen Y. et al.,
2019
Writer KIAA1429 Upregulated KIAA1429, with the aid of GATA3-AS, methylates
GATA3 pre-mRNA, separating HuR and degrading
GATA3 pre-mRNA.
Lan et al., 2019
Eraser FTO Upregulated FTO mechanistically triggers demethylation of PKM2
mRNA and enhances PKM2 translated.
Li et al., 2019
Eraser FTO Downregulated Oncogenic protein SIRT1 downregulates FTO by




Eraser ALKBH5 Downregulated ALKBH5 modulates post-transcriptional inhibition of
LY6/PLAUR domain-containing 1 (LYPD1), which in turn
is stabilized by m6A reader IGF2BP1.
Chen Y. et al.,
2020
Reader YTHDF1 Upregulated Modulates PPAR/NOTCH signaling pathways. Zhao et al.,
2018




Reader YTHDF2 Downregulated Repressed YTHDF2 activity disrupts tumor vasculature




Reader IGFBP3 Downregulated IGFBP-3 regulates growth suppression signals via
altering TGF-β and/or Rb pathways.
Yumoto et al.,
2005
Reader IGF2BP1 Upregulated IGF2BP1 stabilizes c-MYC and MKI67 mRNAs and
enhances c-Myc and Ki-67 protein translation.
Gutschner
et al., 2014
Reader IGF2BP1 Downregulated LINC01093 directly binds IGF2BP1, disrupting
interactions between IGF2BP1 and GLI1 mRNA leading
to the mRNA degradation of the latter.
He et al., 2019
*Based on in vitro and in vivo studies involving patient samples and hepatocellular carcinoma (HCC) cell lines.
Wilms tumor associated protein, another subunit of the
methyltransferase complex that localizes in nuclear speckles, is
highly expressed in HCC and serves as an independent predictor
of hepatocarcinogenesis (Ping et al., 2014; Chen Y. et al.,
2019). WTAP has been shown to promote proliferation and
tumorigenesis by epigenetically silencing the ETS1 transcription
factor (Chen Y. et al., 2019). Accumulating evidence suggests that
ETS proteins regulate various aspects of cancer hallmarks such
as proliferation inducing cell signaling, promoting angiogenesis,
and evading apoptosis through enhanced nuclear transport
(Myers et al., 2005), recruitment of co-repressors (Okamura et al.,
2009), increased DNA binding of nuclear proteins (Sharrocks,
2001), and transactivation of certain genes such as VEGF (Tetsu
and McCormick, 2017; Fry and Inoue, 2018). For example,
ETS1 exhibits preferential binding to wild-type p53, suggesting
tumor-suppressive functions in various cancers (Martinez, 2016).
ETS1 was also shown to directly upregulate genes necessary for
angiogenesis and extracellular matrix remodeling, such as the
matrix metalloproteinases MMP-1, MMP-3, and MMP-9 and
integrin β3 (Oda et al., 1999). Thus, WTAP-mediated epigenetic
silencing of ETS1 could indicate a cogent m6A regulator-driven
tumorigenesis mechanism at play.
KIAA1429, another crucial component of the m6A
methyltransferase complex, is upregulated in HCC cells
exhibiting poor prognosis (Lan et al., 2019). Furthermore,
based on extensive in vitro and in vivo studies, they identified
GATA binding protein 3 (GATA3) as a direct downstream
target of KIAA1429-induced m6A modifications. GATA3 is a
transcription factor composed of two zinc fingers at the carboxyl
terminus, which has been linked with suppression of metastasis,
tumor microenvironment modulation, and promotion of cellular
differentiation (Zheng and Blobel, 2010; Chou et al., 2013;
Siddiqui et al., 2014). KIAA1429, under the guidance of the
long non-coding RNA (lncRNA) GATA3-AS, facilitates m6A
methylation on the 3′-UTR of GATA3 pre-mRNA, disrupting
the activity of the RNA binding protein HuR to GATA3 pre-
mRNA, eventually downregulating GATA3 mRNA expression
(Lan et al., 2019). GATA3 targets one of the classical hallmarks
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of cancer, the capability of tumor cells to induce invasion
and metastasis (Hanahan and Weinberg, 2000; Chou et al.,
2010). In fact, a previous study showed that GATA3-AS drives
hepatocarcinogenesis via metastasis, particularly in HCC, by
suppressing tumor suppressor genes such as p53, PTEN, and key
inhibitors, namely, CDKN1A (Luo et al., 2019).
“Erasers” in Hepatocellular Carcinoma
Hallmarks
Fat mass and obesity-associated protein demethylase is
significantly upregulated in HCC correlating with poor
prognosis, while triggering demethylation of pyruvate kinase 2
(PKM2) mRNA (Li et al., 2019). PKM2, a rate-limiting glycolytic
muscle isozyme, acts as a catalysis mediator in the irreversible
transphosphorylation between adenosine diphosphate and
phosphoenolpyruvate, leading to production of pyruvate and
ATP (Altenberg and Greulich, 2004). In neoplastic cells, PKM2
is overexpressed under the regulation of oncoproteins such as
c-Myc, which activates transcription of hnRNPs, a class of reader
proteins that in turn control mRNA m6A regulation (David
et al., 2010; Liu et al., 2015). PKM2 thus prompts metabolic
reprogramming, a core hallmark of cancer, by facilitating
anabolic metabolism in proliferating cells (Ward and Thompson,
2012). Another study that scrutinized the clinicopathological
features in HCC patients with high PKM2 levels observed poor
prognosis coupled with lower creatinine levels, advanced stage,
and higher grade in such groups (Lu et al., 2018). Although
Gene Expression Profiling Interactive Analysis (GEPIA) and
The Cancer Genome Atlas (TCGA) databases show a strong
correlation between the mRNA expression levels of FTO
and PKM2, the exact dynamics of m6A demethylases and
tumorigenesis inducing altered metabolism portrays a research
gap that is yet to be filled.
Sirtuin 1 (SIRT1), also known as NAD-dependent
deacetylase SIRT1, is frequently upregulated in HCC, where it
regulates chemoresistance and metastasis while maintaining
tumorigenicity and self-renewal capabilities of liver cancer
stem cells (Wilking and Ahmad, 2015; Farcas et al., 2019).
SIRT1 also upregulates oncogenes such as β-catenin (Firestein
et al., 2008), HIF-1α (Laemmle et al., 2012), and c-Myc (Jang
et al., 2012), especially in liver cancers. Functioning as an
oncogene, SIRT1 downregulates m6A demethylase, FTO,
by activating nucleoporin RaBnP2, a protein with a small
ubiquitin-related modifier (SUMO) E3 ligase activity. RaBnP2
triggers SUMOylation of FTO at lysine (K)-216 site leading
to FTO degradation (Liu et al., 2020c). Furthermore, guanine
nucleotide-binding protein G (o) subunit alpha (GNAO1), a
tumor suppressor, is an m6A-mediated downstream target of
FTO. SIRT1 induces downregulation of FTO, thus leading to
degradation of GNAO1, which in turn fuels hepatocarcinogenesis
(Liu et al., 2020c).
AlkB family member 5 demethylase is downregulated in HCC
with the functional role of suppressing proliferation and invasion
capabilities of tumor cells (Chen Y. et al., 2020). Mechanistically,
however, ALKBH5-regulated demethylation leads to post-
transcriptional inhibition of LY6/PLAUR domain-containing 1
(LYPD1), a neurotransmitter receptor-binding protein involved
in the regulation of breast and ovarian cancers, with the potential
to act as a prognostic marker (Wang N. et al., 2019). Given
that, in general, healthy tissues express relatively low levels
of LYPD1 than most peripheral organs (Egerod et al., 2007),
downregulation of ALKBH5 leads to significant upregulation
of LYPD1, an established oncogenic driver of HCC (Chen Y.
et al., 2020). While Chen et al. concluded that an explicit link
between LYPD1 and cancer signaling pathways is yet to be
established, they were able to provide evidence of the involvement
of ALKBH5 in the regulation of P13K/AKT/mTOR and GTPase
pathways, major hallmarks of cancer, through gene ontology and
ALKBH5/LYPD1 gene knockdown studies (Etienne-Manneville
and Hall, 2002; Manning and Toker, 2017; Chen Y. et al., 2020).
Potential involvement of ALKBH5/LYPD1-mediated modulation
could therefore explain the poor prognosis of HCC.
“Readers” in Hepatocellular Carcinoma
Hallmarks
YTH domain-containing family1 m6A reader protein is
significantly upregulated in HCC. Based on gene ontology
and Kyoto Encyclopedia of Genes and Genomes (KEGG)
pathway analyses, YTHDF1 was found to be associated with
p53, NOTCH, and peroxisome proliferator-activated receptors
(PPAR) signaling pathways, which are known to aid in HCC
progression (Han et al., 2019). PPAR Beta/Delta, ligand-
activated transcription factors, have been known to favor
pro-tumorigenicity while being central in the interplay of
different cancer hallmark capabilities, such as cell proliferation,
immune function, induction of angiogenesis, and senescence
and replicative immortality (Wagner and Wagner, 2020). For
example, in HCC cells, PPARγ activation leads to cell growth
inhibition by overexpression of cell cycle arrest-inducing
proteins such as cdc2, p21, p27, and CITED2, in addition to
downregulation of cyclin D1, a protein that promotes cell cycle
(Hsu and Chi, 2014). Contrarily, oxidative stress imposed by
peroxisome proliferators and subsequent induction of PPARα
enables hepatocellular proliferation while inhibiting apoptosis
(Reddy et al., 1976; Tachibana et al., 2008). The NOTCH cell
fate-regulatory pathway, another probable downstream target
of YTHDF1, too, has been shown to be pro-oncogenic, due to
its associations with NOTCH coactivator MAML2, a target of
genetic alterations, and activation of Sox9- and K19-positive
progenitors leading to liver tumorigenesis (Nalesnik et al.,
2012; Strazzabosco and Fabris, 2012; Morell and Strazzabosco,
2014). Thus, the relationship between PPAR/NOTCH signaling
pathways and the epitranscriptomic role of YTHDF1 is an area
that warrants further research.
YTH domain-containing family2 is a novel regulator of
tumor-promoting inflammation (Hou et al., 2019), which
binds to m6A-containing RNAs and directs them to decay
sites for degradation, thereby contributing toward regulating
mRNA stability (Du et al., 2016). YTHDF2 inhibits STAT3
phosphorylation and tumorigenesis through interleukin 11 (IL-
11) mRNA degradation, which encodes IL-6 family cytokine that
triggers HCC with potential for proliferation and metastasis.
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The complex role of IL-11 as a pro-inflammatory cytokine in
regulating immune response through activation of the JAK-
STAT3 signaling pathway, in turn, provides the pro-inflammatory
microenvironment required for malignant transformation and
tumor progression (Bollrath et al., 2009; Kortylewski et al.,
2009). In fact, another recent publication showed that IL-11
levels were significant in postsurgical HCC recurrence due to
the associated enhancement of the IL-11-STAT3 signaling (Wang
D. et al., 2019). Furthermore, YTHDF2 targets the mRNA
degradation of serpin family E member 2 (SERPINE2), a protein
present in the extracellular matrix and known to contribute to
tumor invasion and metastasis through the oncogenic activation
of BRAF, RAS, and MEK, which in turn influence the pro-
neoplastic mechanisms of extracellular signal-regulated kinase
(ERK) signaling (Bergeron et al., 2010; Yang et al., 2018).
YTH domain-containing family2 represses cell proliferation
and activation of MEK and ERK in HCC cells through
modification of 3′-UTR site of EGFR, a key factor in epithelial
malignancies and directing the subsequent degradation of EGFR
mRNA (Zhong et al., 2019). The integrative effects of an
enhanced TGF-α-EGFR-MAPK activity on driving neoplasticity
in HCC cells (Baek et al., 2010), coupled with a range of cancer
hallmarks that EGFR influences, could potentially be negated by
the upregulation of m6A regulator YTHDF2.
IGF 2 mRNA-binding protein3 is regarded as a putative
tumor suppressor as well as mediator of mechanisms involving
growth suppression. Yumoto et al. (2005) postulated that IGFBP3
expression in HCC was concomitant with abnormalities in the
TGF-β receptor and/or effectors of its downstream signaling
pathway such as Rb (Yumoto et al., 2005). It has been shown
that IGFBP3 binds to its putative receptor IGFBP-3R inducing
apoptosis, as well as binds to TGF-β receptor, eventually causing
Smad activation and thereby inducing apoptosis. This reader
protein also activates Stat-1 transcription factor and binds to
nuclear receptors like RXR-α, prompting anti-apoptotic and
anti-proliferative effects (Zappala et al., 2008; Shahjee and
Bhattacharyya, 2014).
IGF 2 mRNA-binding proteins1 is strongly upregulated in
HCC, and it stabilizes and upregulates c-Myc and MK167, two
major regulators of cell proliferation and apoptosis (Gutschner
et al., 2014). This oncofetal reader protein also promotes
the expression of serum response factor (SRF), a critical
transcription factor that regulates cell adhesion, cytoskeletal
regulation, and cell migration, via m6A-mediated impairment
of SRF mRNA decay (Descot et al., 2009; Leitner et al.,
2011; Esnault et al., 2014). At the post-transcriptional level,
IGF2BP1 controls the expression of PDLIM7 and FOXK1,
two genes known to promote HCC hallmarks such as tumor
proliferation and metastasis (Müller et al., 2019). Recently,
another study showed that liver-specific lncRNAs directly bind
IGF2BP1, enabling mRNA degradation of transcription factor
glioma-associated oncogene homolog 1 (GLI1) mRNA, the latter
known to be associated with the hepatocarcinogenesis-inducing
Hedgehog pathway (Della Corte et al., 2017; He et al., 2019).
Another contemporary work revealed that IGF2BP1 stabilizes
the transcript of LINC01138, an oncogenic long intergenic non-
coding RNA that promotes tumorigenesis and tumor invasion
(Li et al., 2018). Thus, it can be postulated that IGF2BP1
reader proteins are involved in a variety of complex downstream




In recent years, immense integrative and comprehensive
genomic and molecular analyses exploring potential diagnostic
and prognostic targets for HCC have brought to light several
prominent therapeutic solutions to curb the burden of HCC.
While the role of genetic and epigenetic mechanisms on the
pathogenesis of hepatocarcinogenesis has been the subject of
extensive research, the network of mechanisms that governs
epitranscriptomics and its associated RNA modifications,
much less its association with liver tumorigenesis, is an
emerging field that warrants further investigation. While the
field of epitranscriptomics has witnessed a rapid upsurge in
research publications in the recent decade, the mechanistic
and functional aspects of m6A regulators and methylation
levels in hepatocarcinogenesis, particularly HCC, still remains
ambiguous, metaphorically signified by the parable of the
“blind men and the elephant.” We are yet to find cogent
answers to prevailing questions such as the following: How
does m6A methylation affect the gene expression regulations
in liver tumorigenesis? Which interwoven regulatory networks
of pathways contribute toward m6A methylation and the
expression of m6A regulator proteins? What m6A-associated
mechanistic pathways are modified by external factors such as
hepatitis B and C, aflatoxin exposure, and other causal factors
of HCC? Do m6A regulators function as oncogenes or tumor
suppressors? Only upon identifying the major cancer hallmark
influencers of epitranscriptomic regulation can we successfully
design therapeutic targets to combat HCC.
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